BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 33473345)

  • 21. Albuterol as an adjunctive treatment to enzyme replacement therapy in infantile-onset Pompe disease.
    Chien YH; Hwu WL; Lee NC; Tsai FJ; Koeberl DD; Tsai WH; Chiu PC; Chang CL
    Mol Genet Metab Rep; 2017 Jun; 11():31-35. PubMed ID: 28480166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New Insights into Gastrointestinal Involvement in Late-Onset Pompe Disease: Lessons Learned from Bench and Bedside.
    Korlimarla A; Lim JA; McIntosh P; Zimmerman K; Sun BD; Kishnani PS
    J Clin Med; 2021 Jul; 10(15):. PubMed ID: 34362174
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessing the Role of Anti rh-GAA in Modulating Response to ERT in a Late-Onset Pompe Disease Cohort from the Italian GSDII Study Group.
    Filosto M; Cotti Piccinelli S; Ravaglia S; Servidei S; Moggio M; Musumeci O; Donati MA; Pegoraro E; Di Muzio A; Maggi L; Tonin P; Marrosu G; Sancricca C; Lerario A; Sacchini M; Semplicini C; Bozzoni V; Telese R; Bonanno S; Piras R; Maioli MA; Ricci G; Vercelli L; Galvagni A; Gallo Cassarino S; Caria F; Mongini T; Siciliano G; Padovani A; Toscano A
    Adv Ther; 2019 May; 36(5):1177-1189. PubMed ID: 30879255
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel approaches to quantify CNS involvement in children with Pompe disease.
    Korlimarla A; Spiridigliozzi GA; Crisp K; Herbert M; Chen S; Malinzak M; Stefanescu M; Austin SL; Cope H; Zimmerman K; Jones H; Provenzale JM; Kishnani PS
    Neurology; 2020 Aug; 95(6):e718-e732. PubMed ID: 32518148
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start.
    Stockton DW; Kishnani P; van der Ploeg A; Llerena J; Boentert M; Roberts M; Byrne BJ; Araujo R; Maruti SS; Thibault N; Verhulst K; Berger KI
    J Neurol; 2020 Oct; 267(10):3038-3053. PubMed ID: 32524257
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
    Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
    Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Behavioral, social and school functioning in children with Pompe disease.
    Korlimarla A; Spiridigliozzi GA; Stefanescu M; Austin SL; Kishnani PS
    Mol Genet Metab Rep; 2020 Dec; 25():100635. PubMed ID: 32793419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of short- and long-term inspiratory muscle training in late-onset Pompe disease (LOPD): a pilot study.
    Wenninger S; Greckl E; Babačić H; Stahl K; Schoser B
    J Neurol; 2019 Jan; 266(1):133-147. PubMed ID: 30430231
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transcriptomic characterization of clinical skeletal muscle biopsy from late-onset Pompe patients.
    Kinton S; Dufault MR; Zhang M; George K
    Mol Genet Metab; 2023 Mar; 138(3):107526. PubMed ID: 36774918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment.
    Montagnese F; Barca E; Musumeci O; Mondello S; Migliorato A; Ciranni A; Rodolico C; De Filippi P; Danesino C; Toscano A
    J Neurol; 2015; 262(4):968-78. PubMed ID: 25673129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment Dilemma in Children with Late-Onset Pompe Disease.
    Faraguna MC; Crescitelli V; Fornari A; Barzaghi S; Savasta S; Foiadelli T; Veraldi D; Paoletti M; Pichiecchio A; Gasperini S
    Genes (Basel); 2023 Jan; 14(2):. PubMed ID: 36833288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Function, structure and quality of striated muscles in the lower extremities in patients with late onset Pompe Disease-an MRI study.
    Vaeggemose M; Mencagli RA; Hansen JS; Dräger B; Ringgaard S; Vissing J; Andersen H
    PeerJ; 2021; 9():e10928. PubMed ID: 33996274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management.
    Kishnani PS; Beckemeyer AA; Mendelsohn NJ
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):1-7. PubMed ID: 22253049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multisystem late onset Pompe disease (LOPD): an update on clinical aspects.
    Toscano A; Rodolico C; Musumeci O
    Ann Transl Med; 2019 Jul; 7(13):284. PubMed ID: 31392196
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review.
    Toscano A; Schoser B
    J Neurol; 2013 Apr; 260(4):951-9. PubMed ID: 22926164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis.
    Schoser B; Stewart A; Kanters S; Hamed A; Jansen J; Chan K; Karamouzian M; Toscano A
    J Neurol; 2017 Apr; 264(4):621-630. PubMed ID: 27372449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Skeletal muscle magnetic resonance imaging in Pompe disease.
    Díaz-Manera J; Walter G; Straub V
    Muscle Nerve; 2021 May; 63(5):640-650. PubMed ID: 33155691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical efficacy of the enzyme replacement therapy in patients with late-onset Pompe disease: a systematic review and a meta-analysis.
    Sarah B; Giovanna B; Emanuela K; Nadi N; Josè V; Alberto P
    J Neurol; 2022 Feb; 269(2):733-741. PubMed ID: 33851281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term whole-body vibration training in two late-onset Pompe disease patients.
    Montagnese F; Thiele S; Wenninger S; Schoser B
    Neurol Sci; 2016 Aug; 37(8):1357-60. PubMed ID: 27193587
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pompe disease in Austria: clinical, genetic and epidemiological aspects.
    Löscher WN; Huemer M; Stulnig TM; Simschitz P; Iglseder S; Eggers C; Moser H; Möslinger D; Freilinger M; Lagler F; Grinzinger S; Reichhardt M; Bittner RE; Schmidt WM; Lex U; Brunner-Krainz M; Quasthoff S; Wanschitz JV
    J Neurol; 2018 Jan; 265(1):159-164. PubMed ID: 29181627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.